Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

This study has been completed.

Sponsor:

Collaborators:

GlaxoSmithKline

Genentech

Information provided by:

Benaroya Research Institute

ClinicalTrials.gov Identifier:

NCT00343044

First received: June 20, 2006

Last updated: May 25, 2010

Last verified: May 2010

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

No publications provided by Benaroya Research Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011 Aug 15;117(16):3731-40. Epub 2011 Feb 24.

To Top